With cancer considerations aside, most evidence to date for the application of HDAC inhibitors exists for neurodegeneration, cardio‐metabolic diseases, liver dysfunction, sarcopenia, inflammation and arthritis, and diseases of premature aging in preclinical mouse studies (Fig 3). The gene discussed is HDAC9; the disease is Decreased liver function.